Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6356 participants.
Also called NCT06186037
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 6,356 participants
- Registry
-
NCT06186037
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06186037. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2029-02-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention
- Acronym
- ALMIGHTY
- Condition
- Coronary Artery Disease
- Condition
- Dyslipidemias
- Condition
- Primary Prevention
- Intervention (Drug)
- Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg
- Intervention (Drug)
- Mono drug group of Rosuvastatin 20 mg
- Lead sponsor
- Saint Vincent's Hospital, Korea
Record details
- Record id
cardio:ct-nct06186037- Content hash
1ca824f26daedd4b7200357be1de61dad70b5927b7b3486fea701580ba075e90